FDA Seeks Feedback on Juice Safety Paperwork—Keep It Fresh and Safe
Published Date: 4/30/2026
Notice
Summary
The FDA is asking for public feedback by June 1, 2026, on their plan to keep juice safe using a system called HACCP, which helps prevent contamination during processing and importing. Juice makers and importers must keep records showing they follow these safety steps. This review keeps the rules clear and up-to-date without adding new costs or deadlines.
Analyzed Economic Effects
4 provisions identified: 1 benefits, 3 costs, 0 mixed.
Estimated Industry Recordkeeping Burden
FDA estimates the total annual recordkeeping burden for juice HACCP at 461,426 hours across affected processors and importers. Major line items include 21,170,000 monitoring records for critical control points that account for 211,700 hours, 102,960 hours for written HACCP plans, and 68,438 hours for sanitation monitoring records.
Mandatory HACCP Records for Juice Firms
If you process or import fruit or vegetable juices, you must establish, follow, and keep Hazard Analysis and Critical Control Point (HACCP) records under 21 CFR part 120 and present them to FDA on inspection. Products not in compliance may be considered adulterated under the Federal Food, Drug, and Cosmetic Act and subject to enforcement action.
Importers Must Keep Written Procedures
Importers of fruit or vegetable juices, or juice ingredients, must have written procedures to ensure processing complies with part 120; FDA lists 308 importers and estimates an annual total burden of 1,232 hours (about 4 hours per importer).
No Capital or O&M Costs Claimed
FDA states there are no capital costs or operating and maintenance (O&M) costs associated with this information collection. The agency notes the burden estimate covers time for recordkeeping but identifies no separate capital or O&M expenditures.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-08415, In the Matter of SHINE Technologies, LLC; SHINE Medical Isotope Production Facility; Direct and Indirect Transfers of License
The Nuclear Regulatory Commission just gave the green light for SHINE Technologies to transfer its construction permit for the SHINE Medical Isotope Production Facility to a new company called SHINE Chrysalis, LLC. This change also involves a new parent company, SHINE Chrysalis Holdings, LLC, and is effective for one year starting April 22, 2026. This move keeps the project on track without any extra costs or delays for now.
Next: 2026-08418, Notice of Request for Revision to and Extension of Approval of an Information Collection; Pale Cyst Nematode
The USDA wants to keep collecting info to stop the pesky pale cyst nematode from spreading across states. They’re updating and extending the paperwork rules that farmers and businesses must follow when moving certain plants. If you’re involved, get ready to share info by June 29, 2026, but don’t worry—this helps protect crops without adding big costs.